Rituximab in post-transplant pediatric recurrent focal segmental glomerulosclerosis Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal, Murine-Derived
  • Glomerulosclerosis, Focal Segmental
  • Immunologic Factors
  • Kidney Transplantation

abstract

  • Rituximab can be used with caution as a treatment for recFSGS. Efficacy is variable from none to complete response. Even partial reduction in proteinuria is of benefit in prolonging the life of the allograft. Long-term, multicenter studies are needed to prove its sustained efficacy in those who respond and to monitor for serious adverse effects.

publication date

  • February 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3541458

Digital Object Identifier (DOI)

  • 10.1007/s00467-012-2314-6

PubMed ID

  • 23052653

Additional Document Info

start page

  • 333

end page

  • 8

volume

  • 28

number

  • 2